126 related articles for article (PubMed ID: 35675855)
1. The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521.
Hall WA; Karrison TG; Rosenthal SA; Amin MB; Gomella LG; Purdy JA; Sartor AO; Michalski JM; Garzotto MG; Bergom C; Jani AB; Lawton CAF; Simko JP; Moore JK; Gore EM; Lee WR; Nguyen PL; Danielson BL; Sandler HM; Feng FY
Int J Radiat Oncol Biol Phys; 2022 Oct; 114(2):266-274. PubMed ID: 35675855
[TBL] [Abstract][Full Text] [Related]
2. The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate.
Hall WA; Nickleach DC; Master VA; Prabhu RS; Rossi PJ; Godette K; Cooper S; Jani AB
Cancer; 2013 Sep; 119(18):3272-9. PubMed ID: 23818401
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy.
Palma D; Tyldesley S; Blood P; Liu M; Morris J; Pickles T;
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1425-9. PubMed ID: 17394943
[TBL] [Abstract][Full Text] [Related]
4. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.
Hallemeier CL; Zhang P; Pisansky TM; Hanks GE; McGowan DG; Roach M; Zeitzer KL; Firat SY; Husain SM; D'Souza DP; Souhami L; Parliament MB; Rosenthal SA; Lukka HR; Rotman M; Horwitz EM; Miles EF; Paulus R; Sandler HM
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1057-1065. PubMed ID: 30959123
[TBL] [Abstract][Full Text] [Related]
5. The 1989 patterns of care study for prostate cancer: five-year outcomes.
Chuba PJ; Moughan J; Forman JD; Owen J; Hanks G
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):325-34. PubMed ID: 11380218
[TBL] [Abstract][Full Text] [Related]
6. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H
JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933
[TBL] [Abstract][Full Text] [Related]
7. Biochemical disease-free survival following 125I prostate implantation.
Beyer DC; Priestley JB
Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):559-63. PubMed ID: 9112453
[TBL] [Abstract][Full Text] [Related]
8. Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
Krauss DJ; Hu C; Bahary JP; Souhami L; Gore EM; Chafe SM; Leibenhaut MH; Narayan S; Torres-Roca J; Michalski J; Zeitzer KL; Donavanik V; Sandler H; McGowan DG; Jones CU; Shipley WU
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):863-73. PubMed ID: 26104939
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy.
Macdonald OK; Schild SE; Vora SA; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
J Urol; 2003 Nov; 170(5):1833-7. PubMed ID: 14532786
[TBL] [Abstract][Full Text] [Related]
10. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
11. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
[TBL] [Abstract][Full Text] [Related]
12. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Rosenthal SA; Hunt D; Sartor AO; Pienta KJ; Gomella L; Grignon D; Rajan R; Kerlin KJ; Jones CU; Dobelbower M; Shipley WU; Zeitzer K; Hamstra DA; Donavanik V; Rotman M; Hartford AC; Michalski J; Seider M; Kim H; Kuban DA; Moughan J; Sandler H
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):294-302. PubMed ID: 26209502
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease.
Latkovskis G; Licis N; Kalnins U
Eur J Immunogenet; 2004 Oct; 31(5):207-13. PubMed ID: 15379752
[TBL] [Abstract][Full Text] [Related]
14. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer.
Ellis RJ; Kaminsky DA; Zhou EH; Fu P; Chen WD; Brelin A; Faulhaber PF; Bodner D
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):29-34. PubMed ID: 20961696
[TBL] [Abstract][Full Text] [Related]
15. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
Crook JM; Zhang P; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Pervez N; Vigneault E; Catton C; Michalski J; Roach M; Beyer D; Jani A; Horwitz E; Donavanik V; Sandler H
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):335-343. PubMed ID: 30312717
[TBL] [Abstract][Full Text] [Related]
16. IL-8 and the innate immunity as biomarkers in acute child and adolescent psychopathology.
Gariup M; Gonzalez A; Lázaro L; Torres F; Serra-Pagès C; Morer A
Psychoneuroendocrinology; 2015 Dec; 62():233-42. PubMed ID: 26325024
[TBL] [Abstract][Full Text] [Related]
17. First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy.
Valicenti RK; Pugh SL; Trabulsi EJ; Sartor O; Ko EC; Girvigian MR; Rosenthal SA; Shaves ME; Hoffman-Censits JH; Schallenkamp J; Sandler HM
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):695-701. PubMed ID: 29413282
[TBL] [Abstract][Full Text] [Related]
18. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
[TBL] [Abstract][Full Text] [Related]
19. Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis.
Guarneri A; Botticella A; Filippi AR; Ruggieri A; Piva C; Munoz F; Ragona R; Gontero P; Ricardi U
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1141-7. PubMed ID: 23552872
[TBL] [Abstract][Full Text] [Related]
20. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Bell EH; Zhang P; Fisher BJ; Macdonald DR; McElroy JP; Lesser GJ; Fleming J; Chakraborty AR; Liu Z; Becker AP; Fabian D; Aldape KD; Ashby LS; Werner-Wasik M; Walker EM; Bahary JP; Kwok Y; Yu HM; Laack NN; Schultz CJ; Gray HJ; Robins HI; Mehta MP; Chakravarti A
JAMA Oncol; 2018 Oct; 4(10):1405-1409. PubMed ID: 29955793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
